Radical radiotherapy for prostate cancer

Cancer Treatment Reviews

Volumn 29, Issue 3, 2003, Pages 161-169

  Parker, C C ^a   Dearnaley, D P ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adjuvant hormone therapy; Dose escalation; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; INSULIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EARLY CANCER; HUMAN; INDIVIDUALIZATION; INSULIN RESISTANCE; MALE; PROSTATE CANCER; PROSTATECTOMY; RADIATION BEAM; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0038481721     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00070-7     Document Type: Review

References (46)

1. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353(9149): 267-272.
2. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53(5): 1111-1116.
3. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48(3): 649-656.
4. Nutting CM, Corbishley CM, Sanchez-Nieto B, et al. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol 2002; 75(890): 151-161.
5. Khoo VS, Padhani AR, Tanner SF, et al. Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol 1999; 72(858): 590-597.
6. Kagawa K, Lee WR, Schultheiss TE, et al. Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38(2): 319-325.
7. Padhani AR, Khoo VS, Suckling J, et al. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys 1999; 44(3): 525-533.
8. Morr J, DiPetrillo T, Tsai JS, et al. Implementation and utility of a daily ultrasound-based localization system with intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53(5): 1124-1129.
9. Wu J, Haycocks T, Alasti H, et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 2001; 61(2): 127-133.
10. Litzenberg D, Dawson LA, Sandler H, et al. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys 2002; 52(3): 699-703.
11. Huang E, Dong L, Chandra A, et al. Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53(2): 261-268.
12. Vicini FA, Abner A, Baglan KL, et al. Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better. Int J Radiat Oncol Biol Phys 2001; 51(5): 1200-1208.
13. Jhaveri FM, Klein EA, Kupelian PA, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999; 17(10): 3167-3172.
14. Smith EB, Frierson Jr HF, Mills SE, et al. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading. Cancer 2002; 94(8): 2282-2287.
15. D'Amico AV, Chen MH, Oh-Ung J, et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radial Oncol Biol Phys 2002; 54(2): 436-441.
16. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53(5): 1097-1105.
17. Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000; 18(14): 2740-2746.
18. Dearnaley D, Aird E, Bidmead AM, et al. High dose conformal radiotherapy in localised prostate cancer: the MRC RT01 randomised trial. Proc ASCO 2002; 21: 769.
19. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337(5):295-300.
20. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50(5): 1243-1252.
21. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37(2): 247-252.
22. Hanks G, Lu J, Machtay M, Venkatesan V, Pinover W, Byhardt R, Rosenthal S. Proc. of Am. Soc. Ther. Rad. Oncol. (ASTRO), RTOG Protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2000; 48: 112.
23. Parker C, Dearnaley D. Re: all-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002; 94(11): 861-862, discussion 865-6.
24. Kirk D. Re: a structured debate - immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment. J Urol 2002; 167(2 Pt-1): 652, discussion 653.
25. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 1997; 82(2): 682-685.
26. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86(9): 4261-4267.
27. Roach M, 3rd, Lu J, Lawton C, et al. A phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: preliminary analysis of RTOG 9413. Int J Radiat Oncol Biol Phys 2002.
28. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 2002; 94(13): 958-960.
29. Nicholson PW, Harland SJ. Survival prospects after screen-detection of prostate cancer. BJU Int 2002; 90(7): 686-693.
30. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17(1): 168-172.
31. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167(4): 1664-1669.
32. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002; 20(16): 3376-3385.
33. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95(2): 281-286.
34. Vicini FA, Martinez A, Hanks G, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002; 95(10): 2126-2135.
35. Schwartz K, Bunner S, Bearer R, et al. Complications from treatment for prostate carcinoma among men in the Detroit area. Cancer 2002; 95(1): 82-89.
36. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92(19): 1582-1592.
37. Madalinska JB, Essink-Bot ML, de Koning HJ, et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19(6): 1619-1628.
38. Choo CR, Danjoux C, Morton GC. Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist's view. Can J Urol 2000; 7(3): 1043-1050.
39. Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol 2001; 61(2): 107-116.
40. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360(9327): 103-106.
41. Thames Jr HD, Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8(2): 219-226.
42. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radial Oncol Biol Phys 1999; 43(5): 1095-1101.
43. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low. Int J Radiat Oncol Biol Phys 2001; 50(4): 1021-1031.
44. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys 2001; 51(1): 213-214.
45. Sanchez-Nieto B, Nahum AE, Dearnaley DP. Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data. Int J Radial Oncol Biol Phys 2001; 49(2): 487-499.
46. Fiorino C, Cozzarini C, Vavassori V, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 2002; 64(1): 1.